≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Postviral fatigue syndrome

DOID EFO Endpoint Browser PheWeb

G6_POSTVIRFAT

chronic fatigue syndrome: a medical condition characterized by long-term fatigue and other symptoms that limit a person's ability to carry out ordinary daily activities.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — G93.3
  • Cause of death: ICD-10 — G93.3

2 out of 7 registries used, show all original rules.

348

4. Check minimum number of events

None

348

5. Include endpoints

None

348

6. Filter based on genotype QC (FinnGen only)

334

Control definitions (FinnGen only)

Control exclude
G6_OTHNEU

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
G93
Name in latin
Syndroma lassitudinis postvirale

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1622 1089 525
Only index persons 1588 1074 514
Unadjusted period prevalence (%)
Whole population 0.03 0.03 0.01
Only index persons 0.03 0.04 0.02
Median age at first event (years)
Whole population 34.76 35.80 32.61
Only index persons 34.81 35.74 32.86

-FinnGen-

Key figures

All Female Male
Number of individuals 334 266 68
Unadjusted period prevalence (%) 0.08 0.09 0.03
Median age at first event (years) 39.94 40.16 39.09

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
348
Matched controls
3480
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G93.3
ICD-10 Finland
Postviral fatigue syndrome
+∞
307.7
348
8
R53
ICD-10 Finland
Malaise and fatigue
10.8
108.0
245
627
R68.88
ICD-10 Finland
Other specified general symptoms and signs, not elsewhere classified.
35.0
78.6
51
17
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
9.0
62.5
90
130
N06AX21
ATC
duloxetine; oral
6.5
55.9
119
259
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
10.5
55.4
67
77
N06AX12
ATC
bupropion; oral
6.6
55.0
111
229
U09.9
ICD-10 Finland
Post COVID-19 condition, unspecified
25.7
54.4
39
17
M79.7
ICD-10 Finland
Fibromyalgia
10.5
52.2
63
72
A04
ICPC
Weakness/tiredness general
5.6
51.9
140
375
N06AX16
ATC
venlafaxine; oral
5.6
51.4
137
363
N04BC05
ATC
pramipexole; oral
9.3
47.5
63
81
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
5.5
46.2
118
298
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
8.1
44.1
66
98
TAB00
NOMESCO Finland
Lumbar puncture
9.0
43.9
59
77
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
8.7
42.0
58
78
F48.0
ICD-10 Finland
Neurasthenia
238.0
41.9
42
*
M35.7
ICD-10 Finland
Hypermobility syndrome
13.5
41.8
41
34
IDY03
NOMESCO Finland
Systematic individual therapy, cognitive-behavioural
6.7
41.3
75
137
Z01.8
ICD-10 Finland
Other specified special examinations
4.6
41.2
142
453
XA800
NOMESCO Finland
Neuropsychological investigation
7.9
36.8
55
81
N03AX12
ATC
[U] gabapentin; oral
4.8
35.0
97
257
G47.3
ICD-10 Finland
Sleep apnoea
4.3
34.3
119
375
F33.11
ICD-10 Finland
Recurrent depression, moderate episode of somatic syndrome
8.7
34.0
46
60
C07AB07
ATC
bisoprolol; oral
3.9
33.5
160
629
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
5.4
32.0
72
159
L28
ICPC
Limited function/disability (L)
4.9
31.8
84
213
A28
ICPC
Limited function/disability NOS
6.1
31.3
61
118
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
8.2
30.4
43
59
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
5.7
29.9
63
131
R42
ICD-10 Finland
Dizziness and giddiness
4.1
29.3
104
329
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.0
29.0
73
177
N03AX16
ATC
[U] pregabalin
3.9
29.0
112
376
R4110
NOMESCO Finland
Physiotherapy
3.6
28.2
133
509
R50.9
ICD-10 Finland
Fever, unspecified
3.9
27.8
104
340
R51.80
ICD-10 Finland
Headache
3.6
27.5
127
478
R03DC03
ATC
montelukast; oral
3.7
27.3
115
407
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
8.0
27.3
39
54
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
7.3
27.0
42
64
H02AB09
ATC
hydrocortisone; systemic
11.2
26.6
29
28
N06AX26
ATC
vortioxetine; oral
4.4
25.8
75
203
G90.8
ICD-10 Finland
Other disorders of autonomic nervous system
+∞
25.3
24
*
N06AX11
ATC
mirtazapine; oral
3.2
25.1
177
853
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
9.4
24.9
31
36
C07AA05
ATC
propranolol; systemic
3.3
24.7
134
552
M79.0
ICD-10 Finland
Rheumatism, unspecified
8.6
24.7
33
42
Q79.6
ICD-10 Finland
Ehlers-Danlos syndrome
58.3
23.4
27
5
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.5
23.3
103
372
N04BC09
ATC
rotigotine; transdermal
70.0
23.2
26
*
R06.0
ICD-10 Finland
Dyspnoea
3.3
23.0
123
500
H02AB06
ATC
prednisolone; systemic
3.0
22.5
196
1046
XF404
NOMESCO Finland
Ambulatory ECG
6.5
22.2
38
64
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
5.0
22.1
52
118
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
22.0
115
459
G43.3
ICD-10 Finland
Complicated migraine
7.1
21.7
34
52
N05BA04
ATC
oxazepam; oral
3.1
21.7
135
596
ZY010
NOMESCO Finland
Hospital outpatient
4.6
21.6
57
142
N06AX22
ATC
agomelatine; oral
6.8
21.4
35
56
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
5.6
21.3
43
85
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
21.1
156
754
N06AB04
ATC
citalopram; systemic
3.2
21.0
107
419
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
222.8
20.8
21
*
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
4.8
20.5
51
121
A01
ICPC
Pain general/multiple sites
4.2
20.4
62
172
N05AH04
ATC
quetiapine; oral
3.1
20.4
119
504
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
4.1
20.2
63
178
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
7.1
19.9
31
47
A02BA02
ATC
ranitidine; systemic
3.7
19.7
74
238
Z2445
NOMESCO Finland
Psychologist
5.0
19.3
45
101
G43.9
ICD-10 Finland
Migraine, unspecified
3.7
19.2
70
221
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
5.6
19.1
38
74
A02BC05
ATC
esomeprazole; systemic
2.8
19.0
166
865
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.2
18.8
55
148
H03AA01
ATC
levothyroxine sodium; systemic
2.9
18.7
117
511
N02BF02
ATC
pregabalin; oral
4.8
18.7
46
108
C01CA24
ATC
epinephrine; parenteral
4.0
18.6
58
164
N06BA07
ATC
modafinil; oral
46.7
18.5
22
5
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.0
18.3
42
93
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
4.0
18.2
58
166
F32.1
ICD-10 Finland
Moderate depressive episode
3.6
18.0
68
219
Z2446
NOMESCO Finland
Social worker
4.4
17.9
49
125
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
3.3
17.6
78
278
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
3.5
17.4
71
240
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
4.0
17.0
53
149
N06CA01
ATC
amitriptyline and psycholeptics; systemic
4.1
16.8
51
141
UJF30
NOMESCO Finland
Ileoscopy through colon
3.9
16.7
54
156
K58.0
ICD-10 Finland
Irritable bowel syndrome with diarrhoea
4.2
16.7
49
132
R03AC02
ATC
salbutamol; inhalant
2.8
16.6
248
1646
XF402
NOMESCO Finland
ECG with work load test
5.4
16.6
34
68
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.6
16.5
151
792
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
3.5
16.5
64
209
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.3
16.5
46
119
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
5.7
16.4
32
61
A02BC02
ATC
pantoprazole; systemic
2.7
16.3
246
1635
R00.2
ICD-10 Finland
Palpitations
3.6
16.1
61
196
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
2.8
16.1
111
505
R00.0
ICD-10 Finland
Tachycardia, unspecified
5.0
15.8
36
79
J45.9
ICD-10 Finland
Asthma, unspecified
2.9
15.7
89
364
B03BA03
ATC
hydroxocobalamin; parenteral
6.6
15.7
26
42
N03AX11
ATC
topiramate; oral
5.4
15.6
32
64
F45.4
ICD-10 Finland
Persistent somatoform pain disorder
12.1
15.6
28
25
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.1
15.6
75
280
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
4.3
15.5
43
111
SHA02
NOMESCO Finland
Stomatognathic treatment, basic
3.3
15.3
66
230
A03FA01
ATC
metoclopramide; systemic, rectal
2.8
15.3
100
441
N06AG02
ATC
moclobemide; oral
6.1
15.2
27
47
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
5.1
15.0
33
70
N06BA04
ATC
methylphenidate; oral
3.7
14.9
52
158
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
14.6
64
225
F41.1
ICD-10 Finland
Generalized anxiety disorder
3.3
14.6
62
214
SPAT1215
SPAT
Assessment of need for medical rehabilitation
6.3
14.5
25
42
N06AB03
ATC
fluoxetine; oral
3.2
14.5
66
238
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.5
14.5
55
177
XQ800
NOMESCO Finland
Prick test
3.6
14.2
52
163
K30
ICD-10 Finland
Functional dyspepsia
3.1
14.1
66
241
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.4
14.1
177
1054
N17
ICPC
Vertigo/dizziness
3.3
14.0
60
208
F43.1
ICD-10 Finland
Post-traumatic stress disorder
4.2
13.9
39
101
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.7
13.7
95
429
N06AB06
ATC
sertraline; oral
2.8
13.7
81
338
R52.2
ICD-10 Finland
Other chronic pain
5.2
13.6
29
60
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
5.2
13.6
29
60
R52.9
ICD-10 Finland
Pain, unspecified
3.3
13.5
58
201
N04BD01
ATC
selegiline; oral
27.0
13.5
18
7
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.9
13.3
41
114
R11
ICD-10 Finland
Nausea and vomiting
3.3
13.3
56
192
SPAT1229
SPAT
Assessment of need for aid
6.2
13.2
23
39
F34.1
ICD-10 Finland
Dysthymia
4.4
13.2
35
87
M79.1
ICD-10 Finland
Myalgia
2.6
13.0
92
419
N06AA09
ATC
amitriptyline; systemic
3.9
13.0
40
111
R5140
NOMESCO Finland
Monitoring the use of the aid
3.6
12.8
45
137
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
6.3
12.8
22
37
Z02.7
ICD-10 Finland
Issue of medical certificate
3.5
12.7
47
148
M03BX01
ATC
baclofen; systemic
10.7
12.7
24
24
G43.8
ICD-10 Finland
Other migraine
5.9
12.6
23
41
N06AB10
ATC
escitalopram; oral
2.4
12.6
124
658
G44.2
ICD-10 Finland
Tension-type headache
2.6
12.5
86
386
ICB03
NOMESCO Finland
Psychiatric treatment plan, monitoring
5.7
12.5
24
45
N03AE01
ATC
clonazepam; systemic
4.6
12.5
31
73
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.6
12.5
31
73
M54.2
ICD-10 Finland
Cervicalgia
3.2
12.4
55
194
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
3.9
12.4
38
105
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
4.2
12.4
35
91
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.6
12.4
87
394
XKD00
NOMESCO Finland
Uroflowmetry
4.8
12.4
29
65
N02AX02
ATC
tramadol; systemic, rectal
2.3
12.4
148
852
R20.2
ICD-10 Finland
Paraesthesia of skin
3.4
12.2
48
157
R4120
NOMESCO Finland
Occupational therapy
3.8
12.2
39
111
R96
ICPC
Asthma
3.5
12.2
46
147
N28
ICPC
Limited function/disability (N)
22.2
12.1
17
8
3007
Kela drug reimbursment
Erenumab and fremanezumab
6.0
12.1
22
39
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
6.0
12.1
22
39
F51.0
ICD-10 Finland
Nonorganic insomnia
2.4
11.9
113
587
R03BA08
ATC
ciclesonide; inhalant
3.3
11.8
49
166
J01MA02
ATC
ciprofloxacin; systemic
2.3
11.7
126
691
OAB93, ,
SPAT
2.9
11.6
60
231
G47.8
ICD-10 Finland
Other sleep disorders
5.1
11.6
25
52
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
2.8
11.5
65
263
Z71.8
ICD-10 Finland
Other specified counselling
2.2
11.5
168
1041
SHB00
NOMESCO Finland
Preparing and fitting the occlusal splint in the mouth
2.5
11.4
83
382
N05CF02
ATC
zolpidem; oral
2.6
11.3
80
362
H04.10
ICD-10 Finland
Dry eye syndrome
2.8
11.3
63
253
IGY99
NOMESCO Finland
Other psychiatric treatment contact
4.5
11.2
28
66
Z3231
NOMESCO Finland
Registered nurse
2.3
11.2
110
578
J01FA09
ATC
clarithromycin; systemic
2.2
11.2
139
806
AA1BG, ,
SPAT
6.0
11.1
20
35
Z3226
NOMESCO Finland
Physiotherapist
2.6
11.1
74
325
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.8
11.1
65
268
M25.5
ICD-10 Finland
Pain in joint
2.2
11.0
152
918
J31.0
ICD-10 Finland
Chronic rhinitis
2.9
10.9
56
215
I49.9
ICD-10 Finland
Cardiac arrhythmia, unspecified
2.7
10.9
67
283
H02AA02
ATC
fludrocortisone; oral
61.9
10.7
12
*
R1240
NOMESCO Finland
Social assessment of need and possibilities of rehabilitation
11.7
10.7
19
17
F60.5
ICD-10 Finland
Anankastic personality disorder
11.7
10.7
19
17
IBA04
NOMESCO Finland
Extensive initial psychiatric evaluation
5.3
10.7
22
44
R13
ICD-10 Finland
Dysphagia
4.1
10.6
30
78
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
2.4
10.6
86
415
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.0
10.6
50
183
AA1AD
NOMESCO Finland
CT of head and brain
2.5
10.5
75
340
N02CC03
ATC
zolmitriptan; nasal, oral
3.2
10.5
45
155
J01AA02
ATC
doxycycline; systemic
2.4
10.5
267
2027
R4110, ,
SPAT
2.9
10.4
53
202
U09
ICD-10 Finland
Post COVID-19 condition
11.1
10.4
19
18
K58.9
ICD-10 Finland
Irritable bowel syndrome without diarrhoea
5.0
10.4
23
49
J45.0
ICD-10 Finland
Predominantly allergic asthma
2.9
10.3
54
209
N02BF01
ATC
gabapentin; oral
3.0
10.3
49
180
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
4.0
10.3
30
80
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
3.9
10.2
31
85
R03BA05
ATC
fluticasone; inhalant
2.4
10.2
88
436
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
10.5
10.1
19
19
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.1
10.1
133
781
K07.60
ICD-10 Finland
Snapping jaw
3.1
10.1
44
153
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
15.2
10.1
16
11
R02
ICPC
Shortness of breath/dyspnoea
2.8
10.0
55
219
R4190
NOMESCO Finland
Nutritional therapy
3.9
9.9
30
82
WX723
NOMESCO Finland
CPAP therapy
4.8
9.9
23
51
N05AB03
ATC
perphenazine; systemic, rectal
5.1
9.9
21
43
N07AA02
ATC
pyridostigmine; systemic
20.8
9.9
14
7
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
9.7
75
352
G44.8
ICD-10 Finland
Other specified headache syndromes
8.8
9.7
20
24
G50.1
ICD-10 Finland
Atypical facial pain
10.5
9.6
18
18
ZXD31
NOMESCO Finland
Major difficulties in performing procedure
4.3
9.6
25
61
N06AX03
ATC
mianserin; oral
4.3
9.6
25
61
UJF32
NOMESCO Finland
Coloscopy
2.4
9.6
75
354
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.2
9.5
98
521
R06AE07
ATC
cetirizine; oral
2.0
9.5
188
1276
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
4.2
9.5
26
66
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
5.4
9.5
19
37
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
31.0
9.5
12
*
N05CF01
ATC
zopiclone; oral
2.2
9.4
106
584
ICC04
NOMESCO Finland
Psychiatric treatment plan, permanent discontinuation
4.1
9.3
26
67
A06AC01
ATC
ispaghula (psylla seeds); oral
2.3
9.3
88
451
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
3.6
9.3
31
91
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
3.6
9.3
32
96
G47.9
ICD-10 Finland
Sleep disorder, unspecified
4.2
9.2
25
63
F33.1
ICD-10 Finland
Recurrent depressive disorder, current episode moderate
3.5
9.1
32
97
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
2.3
9.1
80
397
G54.0
ICD-10 Finland
Brachial plexus disorders
4.4
9.1
23
55
T78.4
ICD-10 Finland
Allergy, unspecified
3.6
9.0
31
93
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.0
8.8
137
849
ZXY01
NOMESCO Finland
Chief Physician, Head of Department or Deputy Chief Physician
8.0
8.8
19
25
Z01.9
ICD-10 Finland
Special examination, unspecified
3.5
8.7
31
95
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.3
8.7
82
419
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
12.0
8.7
15
13
P29
ICPC
Psychological sympt/compl other
2.5
8.6
61
274
R01AD05
ATC
budesonide; nasal
3.1
8.6
38
133
ZYC01
NOMESCO Finland
Remote contact by phone
3.2
8.6
36
122
R07.4
ICD-10 Finland
Chest pain, unspecified
2.2
8.6
85
442
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.6
8.6
29
86
M01AH01
ATC
celecoxib; oral
2.6
8.5
54
230
L19
ICPC
Muscle symptom/complaint NOS
4.5
8.5
21
49
M03BC01
ATC
orphenadrine (citrate); systemic
2.1
8.5
105
596
N05BA01
ATC
diazepam; systemic, rectal
2.7
8.5
48
193
WZC00
NOMESCO Finland
Treatment plan or consultation
2.0
8.5
144
916
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
2.6
8.5
51
212
R06.5
ICD-10 Finland
Mouth breathing
2.9
8.4
41
152
F41.09
ICD-10 Finland
UNS Panic Syndrome
3.7
8.4
27
77
SPAT1216
SPAT
Assessment of functional ability
3.0
8.3
38
136
R51.81
ICD-10 Finland
Facial pain NOS
6.8
8.3
20
31
M01AE02
ATC
naproxen; oral, rectal
2.0
8.3
229
1714
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
4.6
8.3
20
46
C09CA06
ATC
candesartan; oral
2.2
8.2
84
442
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
8.2
86
458
K59.09
ICD-10 Finland
Constipation, unspecified
3.8
8.2
25
69
R07.0
ICD-10 Finland
Pain in throat
2.7
8.2
48
197
D01
ICPC
Abdominal pain/cramps general
2.3
8.2
69
336
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
17.7
8.1
12
7
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
9.3
8.1
16
18
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.2
8.1
74
373
J45.1
ICD-10 Finland
Nonallergic asthma
3.3
8.0
31
100
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.9
8.0
158
1052
N03AX09
ATC
lamotrigine; oral
3.0
8.0
37
133
N02CC05
ATC
almotriptan; oral
3.2
8.0
33
111
N06AX05
ATC
trazodone; oral
6.4
8.0
20
33
R06AX13
ATC
loratadine; oral
2.2
8.0
76
389
R01AD12
ATC
fluticasone furoate; nasal
1.9
8.0
154
1019
Z2221
NOMESCO Finland
Medical doctor
2.0
7.9
118
714
IBA01, ,
SPAT
4.2
7.9
21
52
U08.9
ICD-10 Finland
Personal history of COVID-19, unspecified
11.2
7.9
14
13
P01
ICPC
Feeling anxious/nervous/tense
2.1
7.8
98
557
N92.6
ICD-10 Finland
Irregular menstruation, unspecified
2.5
7.8
52
227
S13.4
ICD-10 Finland
Sprain and strain of cervical spine
3.2
7.8
31
102
F41.8
ICD-10 Finland
Other specified anxiety disorders
3.2
7.8
31
102
LCA06
NOMESCO Finland
Biopsy of endometrium
2.3
7.8
63
301
A11
ICPC
Chest pain NOS
3.3
7.7
29
92
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
3.8
7.7
24
67
M01AC06
ATC
meloxicam; systemic, rectal
2.0
7.7
110
655
A29
ICPC
General symptom/complaint other
2.5
7.7
53
235
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
3.6
7.7
26
77
F33.00
ICD-10 Finland
Recurrent depression, mild episode without somatic syndrome
4.0
7.6
22
58
N99
ICPC
Neurological disease other
18.9
7.6
11
6
J02AC01
ATC
fluconazole; systemic
1.9
7.6
175
1219
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
9.2
7.6
15
17
A02BA03
ATC
famotidine; systemic
10.4
7.6
14
14
R06AX26
ATC
fexofenadine; oral
2.7
7.6
43
173
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
7.6
127
798
R03AK11
ATC
formoterol and fluticasone; inhalant
6.7
7.5
18
28
Z3229
NOMESCO Finland
Other healthcare associate professional
3.2
7.5
30
99
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.3
7.4
28
89
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
13.8
7.4
12
9
K59.1
ICD-10 Finland
Functional diarrhoea
3.6
7.4
25
74
G44.0
ICD-10 Finland
Cluster headache syndrome
7.1
7.4
17
25
N05BE01
ATC
buspirone; oral
4.3
7.4
19
46
N80.0
ICD-10 Finland
Endometriosis of uterus
4.3
7.4
19
46
P03
ICPC
Feeling depressed
2.2
7.4
74
386
E61.1
ICD-10 Finland
Iron deficiency
3.2
7.3
29
95
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
+∞
7.3
7
*
I49.8
ICD-10 Finland
Other specified cardiac arrhythmias
4.5
7.3
18
42
J45
ICD-10 Finland
Asthma
2.5
7.3
50
221
P76
ICPC
Depressive disorder
2.5
7.3
50
221
N06AB05
ATC
paroxetine; oral
3.0
7.3
32
112
F51.9
ICD-10 Finland
Nonorganic sleep disorder, unspecified
4.1
7.3
20
51
A02BC04
ATC
rabeprazole; oral
2.6
7.3
43
177
C10AC01
ATC
colestyramine; oral
4.7
7.3
17
38
G04CA01
ATC
alfuzosin; oral
4.7
7.3
17
38
P01AB01
ATC
metronidazole; oral, rectal
1.9
7.2
153
1034
NXL00
NOMESCO Finland
Biopsy of muscle
30.7
7.2
9
*
L99
ICPC
Musculoskeletal disease other
5.8
7.2
19
34
JN3AD
NOMESCO Finland
Abdominal CT examination
2.6
7.1
45
191
Z31.5
ICD-10 Finland
Genetic counselling
2.8
7.1
38
148
F33.01
ICD-10 Finland
Recurrent depression, mild episode of somatic syndrome
12.4
7.1
12
10
SPAT1301
SPAT
No procedures
2.0
7.1
105
630
M47.80
ICD-10 Finland
Other spondylosis, multiple sites in spine
9.1
7.1
14
16
N05AX12
ATC
aripiprazole; systemic
2.9
7.1
35
131
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.7
7.1
39
155
M79.6
ICD-10 Finland
Pain in limb
1.8
7.0
165
1148
IGY02
NOMESCO Finland
Psychiatric monitoring contact
3.1
7.0
30
103
M54.5
ICD-10 Finland
Low back pain
1.8
7.0
150
1014
N94.1
ICD-10 Finland
Dyspareunia
6.6
7.0
17
27
ICB02
NOMESCO Finland
Psychiatric treatment plan, extended/prolonged
6.1
7.0
18
31
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
2.6
7.0
42
174
E0000UV, ,
ATC
1.8
7.0
160
1106
F32.00
ICD-10 Finland
Mild depressive episode without somatic syndrome
3.1
6.9
30
104
SHA03
NOMESCO Finland
Stomatognathic treatment, demanding
3.3
6.9
26
83
R4120, ,
SPAT
11.2
6.8
12
11
R29
ICPC
Respiratory symptom/complaint other
2.7
6.8
38
152
R05
ICD-10 Finland
Cough
2.0
6.8
85
481
A03
ICPC
Fever
2.0
6.8
93
544
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.9
6.7
32
117
R01AD08
ATC
fluticasone; nasal
1.9
6.7
122
781
J05AB11
ATC
valaciclovir; oral
2.2
6.7
62
312
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.6
6.7
39
159
IBZ02
NOMESCO Finland
Somatic assessment of psychiatric patient
23.0
6.7
9
*
T91
ICPC
Vitamin/nutritional deficiency
23.0
6.7
9
*
F33
ICD-10 Finland
Recurrent depressive disorder
3.7
6.7
21
59
H53.2
ICD-10 Finland
Diplopia
6.1
6.7
17
29
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
2.4
6.7
46
204
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
3.2
6.7
27
90
N06BA12
ATC
lisdexamfetamine; oral
4.0
6.6
19
50
ZX120
NOMESCO Finland
Intravenous
2.8
6.6
34
130
OAB74
NOMESCO Finland
Nutritional guidance related to treatment and rehabilitation for medical condition
9.0
6.6
13
15
N29
ICPC
Neurological sympt/complt other
7.1
6.6
15
22
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
7.1
6.6
15
22
N06AX17
ATC
milnacipran; oral
10.3
6.6
12
12
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.4
6.6
24
75
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.2
6.5
60
301
UJF92
NOMESCO Finland
Capsular endoscopy
5.9
6.5
17
30
R06AX22
ATC
ebastine; oral
2.0
6.5
81
457
F33.4
ICD-10 Finland
Recurrent depressive disorder, currently in remission
3.2
6.5
25
81
R51
ICD-10 Finland
Headache
2.6
6.4
38
156
ICB07, ,
NOMESCO Finland
71.1
6.4
7
*
A02BC01
ATC
omeprazole; systemic
2.0
6.4
86
497
R21
ICPC
Throat symptom/complaint
1.8
6.4
131
868
N02CD03
ATC
fremanezumab; systemic
5.7
6.4
17
31
M03AX01
ATC
botulinum toxin; parenteral
6.2
6.4
16
27
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
2.1
6.4
68
362
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
3.0
6.4
28
98
A07AA02
ATC
nystatin; oral
4.0
6.3
18
47
F29
ICPC
Eye symptom/complaint other
2.3
6.3
48
222
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
3.1
6.3
27
93
R68.81
ICD-10 Finland
A constant or recurrent sensitivity to experience symptoms and signs in relation to common factors in the environment, not elsewhere classified.
18.4
6.3
9
5
P99
ICPC
Psychological disorders other
3.3
6.3
24
77
R1210
NOMESCO Finland
Medical assessment of need and possibilities to rehabilitation
7.2
6.3
14
20
N89
ICPC
Migraine
2.7
6.3
35
140
H02
ICPC
Hearing complaint
2.7
6.2
34
134
R03AC12
ATC
salmeterol; inhalant
4.1
6.2
17
43
F90.0
ICD-10 Finland
Disturbance of activity and attention
2.5
6.2
42
184
OAA68, ,
SPAT
5.9
6.2
16
28
A04AA01
ATC
ondansetron; systemic, rectal
2.8
6.2
31
117
D09
ICPC
Nausea
2.7
6.2
34
135
R33
ICD-10 Finland
Retention of urine
4.3
6.2
16
39
J01FF01
ATC
clindamycin; systemic
1.9
6.1
93
560
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
3.7
6.1
19
53
N06AX18
ATC
reboxetine; oral
12.8
6.1
10
8
A99
ICPC
Disease/condition unspecnature/site
2.5
6.1
40
173
R06.4
ICD-10 Finland
Hyperventilation
6.9
6.1
14
21
N06AA10
ATC
nortriptyline; systemic
5.4
6.1
17
33
S01GX01
ATC
cromoglicic acid; ophthalmic
1.9
6.1
101
626
R69
ICD-10 Finland
Unknown and unspecified causes of morbidity
6.2
6.1
15
25
M01AE03
ATC
ketoprofen; systemic, rectal
1.9
6.0
103
644
A02BC03
ATC
lansoprazole; oral
1.9
6.0
84
492
H02AB07
ATC
prednisone; oral
2.3
6.0
45
207

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 500 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Proper column names.
  • Show details (e.g. Fisher or Chi-square test, N cases and N controls) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV not working.
  • No filters and sorters.
  • Limited amount of endpoints with TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP Concept
ln(OR) -5y
ln(OR) -1y
ln(OR) -1m
ln(OR) d0
ln(OR) +1m
ln(OR) +1y
ln(OR) +5y
MCC -5y
MCC -1y
MCC -1m
MCC d0
MCC +1m
MCC +1y
MCC +5y
Postviral fatigue syndrome
G93.3 (45595967)
Other disorders of autonomic nervous system
G90.8 (45533172)
Neurasthenia
F48.0 (45557209)
Post COVID-19 condition, unspecified
U09.9 (710706)
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 (2002330113)
Body height measure
50373000 (4177340)
Body mass index
60621009 (4245997)
Fibromyalgia
M79.7 (45553272)
Fever, unspecified
R50.9 (45582716)
Hypermobility syndrome
M35.7 (45601437)
Recurrent depression, moderate episode without somatic syndrome
F33.10 (2000501984)
Recurrent depression, moderate episode of somatic syndrome
F33.11 (2000501985)
Other specified general symptoms and signs, not elsewhere classified.
R68.88 (2000503606)
Systematic individual therapy, cognitive-behavioural
IDY03 (2001304164)
Multidisciplinary treatment meeting
WZC20 (2001310890)
rotigotine; transdermal
N04BC09 (21604481)
Acetylcholine receptor Ab [Moles/volume] in Serum
20427-1 (3006257)
Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 (3007080)
Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
5159-9 (3007844)
Metanephrine [Moles/volume] in Serum or Plasma
25473-0 (3009340)
Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay
5257-1 (3010521)
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 (3021614)
Normetanephrine [Moles/volume] in Serum or Plasma
25489-6 (3026179)
Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
5253-0 (3027545)
3-Methoxytyramine [Moles/volume] in Serum or Plasma
50140-3 (3030408)
Metanephrine Free [Moles/volume] in Serum or Plasma
49700-8 (3032155)
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 (3041942)
Epstein Barr virus Ab [Presence] in Serum
49178-7 (3048929)
General Practice
1 (38004446)
Cardiology
6 (38004451)
Physical Medicine And Rehabilitation
25 (38004468)
Pulmonary Disease
29 (38004472)
Infectious Disease
44 (38004484)
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 (45534452)
Care involving use of other rehabilitation procedures
Z50.8 (45556842)
Predominantly allergic asthma
J45.0 (45557624)
Sleep apnoea
G47.3 (45562094)
Mixed anxiety and depressive disorder
F41.2 (45566845)
Ehlers-Danlos syndrome
Q79.6 (45587483)
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 (45587505)
Observation for suspected nervous system disorder
Z03.3 (45609903)
Malaise and fatigue
R53 (45553741)
Cortisol [Moles/volume] in Serum or Plasma
14675-3 (3036481)
Psychiatry
26 (38004469)
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 (3007220)
Neurology
13 (38004458)
IgG [Mass/volume] in Serum or Plasma
2465-3 (3005719)
duloxetine; oral
N06AX21 (21604749)
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 (45547705)
Generalized anxiety disorder
F41.1 (45571764)
Pharmacy visit
OMOP4822462 (581458)
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 (43054903)
pramipexole; oral
N04BC05 (21604477)
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 (3034780)
bupropion; oral
N06AX12 (21604741)
Other specified special examinations
Z01.8 (45581003)
Physiotherapy
R4110 (2001310233)
Neuropsychological investigation
XA800 (2001300412)
valaciclovir; oral
J05AB11 (21603137)
Dysthymia
F34.1 (45586238)
pregabalin; oral
N02BF02 (955152)
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 (3008230)
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 (3021347)
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 (3013707)
IgA [Mass/volume] in Serum or Plasma
2458-8 (3007164)
Sodium [Moles/volume] in Serum or Plasma
2951-2 (3019550)
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 (3016431)
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 (3016888)
Potassium [Moles/volume] in Serum or Plasma
2823-3 (3023103)
Transferrin [Mass/volume] in Serum or Plasma
3034-6 (3004789)
Outpatient Visit
OP (9202)
montelukast; oral
R03DC03 (21603356)
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 (40763571)
Internal Medicine
11 (38004456)
Iron [Moles/volume] in Serum or Plasma
14798-3 (3022948)
Standard MRI examination of brain with high intensity magnet
AA1BG (2001300112)
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 (3017918)
pH of Serum or Plasma
2753-2 (3018418)
Extractable nuclear Ab [Units/volume] in Serum
30342-0 (3015171)
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 (40771025)
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 (40764999)
Osmolality of Urine
2695-5 (3026782)
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 (3017766)
Basophils/Leukocytes in Blood
30180-4 (3022096)
Eosinophils/Leukocytes in Blood
26450-7 (3006504)
Monocytes/Leukocytes in Blood
26485-3 (3019069)
Limited function/disability NOS
A28 (2002000162)
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 (3020460)
Neutrophils/Leukocytes in Blood
26511-6 (3018010)
Lymphocytes/Leukocytes in Blood
26478-8 (3002030)
Calcium [Moles/volume] in Serum or Plasma
2000-8 (3015377)
propranolol; oral, parenteral
C07AA05 (21601670)
Dizziness and giddiness
R42 (45568132)
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 (3015635)
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 (3000620)
General psychiatric examination, not elsewhere classified
Z00.4 (45605094)
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 (3010130)
venlafaxine; oral
N06AX16 (21604745)
Basophils [#/volume] in Blood
26444-0 (3006315)
Dyspnoea
R06.0 (45558449)
Monocytes [#/volume] in Blood
26484-6 (3001604)
Magnesium [Moles/volume] in Serum or Plasma
2601-3 (3012095)
Lymphocytes [#/volume] in Blood
26474-7 (3019198)
Ferritin [Mass/volume] in Serum or Plasma
2276-4 (3001122)
Eosinophils [#/volume] in Blood
26449-9 (3013115)
Limited function/disability (L)
L28 (2002000647)
Asthma, unspecified
J45.9 (45562456)
Creatinine [Moles/volume] in Serum or Plasma
14682-9 (3020564)
Ammonium ion [Moles/volume] in Plasma
1845-7 (3023183)
Supplier / Service Provider
OMOP5117446 (33004)
Differential panel, method unspecified - Blood
69738-3 (42870588)
Weakness/tiredness general
A04 (2002000145)
Case Management Agency
251B00000X (38004193)
epinephrine; parenteral
C01CA24 (21600303)
epinephrine
S01EA01 (21603673)
Folate [Moles/volume] in Serum or Plasma
14732-2 (3021960)
Care involving use of rehabilitation procedure, unspecified
Z50.9 (45595525)
Headache
R51.80 (2000503603)
FEV1/FVC
19926-5 (3011505)
Forced vital capacity [Volume] Respiratory system
19870-5 (3020158)
FEV1
20150-9 (3024653)
oxazepam; oral
N05BA04 (21604569)
Nuclear Ab [Titer] in Serum
29953-7 (3037522)
CBC W Ordered Manual Differential panel - Blood
57782-5 (40760892)
Occupational therapy
R4120 (2001310234)
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 (3015399)
doxycycline; oral, parenteral
J01AA02 (21602800)
Albumin [Mass/volume] in Serum or Plasma
1751-7 (3024561)
melatonin; oral
N05CH01 (21604659)
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 (3026989)
Neutrophils [#/volume] in Blood by Automated count
751-8 (3013650)
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 (3022250)
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 (3035995)
IgM [Mass/volume] in Serum or Plasma
2472-9 (3028026)
Normoblasts [#/volume] in Blood
715-3 (3021589)
Gas panel - Central venous blood
97535-9 (1616796)
Other specified counselling
Z71.8 (45581061)
Otolaryngology
4 (38004449)
nortriptyline; oral, parenteral
N06AA10 (21604697)
Migraine, unspecified
G43.9 (45595943)
Other and unspecified abdominal pain
R10.4 (45568113)
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 (3002385)
12 lead EKG panel
34534-8 (3044889)
amitriptyline; oral, parenteral
N06AA09 (21604696)
Rheumatology
66 (38004491)
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 (3027238)
pH of Blood
11558-4 (3010421)
Erythrocytes [#/volume] in Urine
30391-7 (3002582)
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 (3013721)
Platelets [#/volume] in Blood
26515-7 (3007461)
MCV [Entitic mean volume] in Red Blood Cells
30428-7 (3024731)
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 (3009542)
MCH [Entitic mass]
28539-5 (3035941)
Leukocytes [#/volume] in Urine
30405-5 (3018095)
Erythrocytes [#/volume] in Blood
26453-1 (3026361)
Leukocytes [#/volume] in Blood
26464-8 (3010813)
Hemoglobin [Mass/volume] in Blood
718-7 (3000963)
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 (3008486)
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 (3009201)
Short blood count panel - Blood
55429-5 (40758558)
Office Visit
OMOP4822458 (581477)
ranitidine; oral, parenteral
A02BA02 (21600083)
ranitidine bismuth citrate; oral
A02BA07 (21600088)
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 (3019800)
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 (3029287)
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 (3019050)
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 (3020059)
Folate [Moles/volume] in Red Blood Cells
14731-4 (3019309)
bisoprolol; oral
C07AB07 (21601689)
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 (2001310246)
methylphenidate; oral
N06BA04 (21604757)
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 (3009035)
salbutamol; inhalant
R03AC02 (21603256)
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 (3051714)
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 (3006140)
prednisolone
A07EA01 (21600653)
prednisolone; oral, parenteral
H02AB06 (21602734)
Laboratory Visit
OMOP4822461 (32036)
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 (3003338)
gabapentin; oral
N02BF01 (955005)
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 (3006923)
mirtazapine; oral
N06AX11 (21604740)
metoclopramide; oral, parenteral, rectal
A03FA01 (21600484)
esomeprazole; oral, parenteral
A02BC05 (21600100)
Leukocytes [#/volume] in Cerebral spinal fluid
26465-5 (3016543)
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 (3027475)
Lumbar puncture
TAB00 (2001300538)
Glucose [Moles/volume] in Cerebral spinal fluid
14744-7 (3020044)
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 (3019473)
C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method
30522-7 (3010156)
pantoprazole; oral, parenteral
A02BC02 (21600097)
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 (3016293)
Base excess in Blood by calculation
11555-0 (3012501)
Carbon dioxide [Partial pressure] in Blood
11557-6 (3013290)
Oxygen [Partial pressure] in Blood
11556-8 (3027315)
quetiapine; oral
N05AH04 (21604544)
Gastroenterology
10 (38004455)
fluconazole; oral, parenteral
J02AC01 (21603080)
Acute upper respiratory infection, unspecified
J06.9 (45562437)
Pain localized to other parts of lower abdomen
R10.3 (45534426)
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 (3029879)
Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid
22126-7 (3010380)

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
204
295
15.30
152.93
2.6
1.9
386.22
376.44
nmol/l
0.29
195
278
171
230
13.65
133.00
2.9
2.3
30.62
17.63
au/ml
—
9
29
196
520
7.34
78.14
1.8
1.4
223.78
460.58
titre
4.46
37
103
83
84
12.66
75.92
1.3
1.4
258.05
170.03
u/ml
2.34
59
51
77
77
12.56
70.79
1.3
1.5
—
—
—
0
0
118
236
7.05
60.85
3.0
2.5
10.02
10.31
g/l
0.46
107
227
101
175
7.72
59.66
1.4
1.3
—
—
—
0
0
249
1020
6.07
56.20
2.4
1.8
99.58
96.28
pmol/l
0.49
145
586
128
300
6.17
55.54
2.8
2.4
28.52
24.14
%
3.36
121
281
141
367
5.78
54.35
3.1
2.3
16.67
14.33
umol/l
3.74
133
343
132
334
5.76
52.29
3.0
2.3
2.45
2.46
g/l
0.07
127
306
237
983
5.42
51.14
5.1
6.5
1.22
1.22
mmol/l
0.08
229
919
253
1135
5.50
48.66
5.7
6.5
1.22
1.21
mmol/l
0.13
225
994
271
1313
5.81
46.54
3.5
2.6
76.89
72.58
nmol/l
1.73
263
1248
44
39
12.77
43.07
1.3
2.2
—
—
—
0
0
145
458
4.71
42.84
1.8
1.6
453.98
64048035.28
pmol/l
1.04
137
420
218
952
4.45
41.18
6.6
6.7
—
—
—
0
0
41
36
12.78
40.31
1.7
1.4
23.04
30.30
ng/l
0.33
41
36
169
631
4.26
39.31
1.8
1.5
20.75
20.85
nmol/l
0.02
159
577
220
997
4.28
38.73
3.9
4.8
38.27
37.54
g/l
1.54
210
956
121
358
4.65
38.35
2.9
3.6
0.84
0.82
mmol/l
1.39
113
342
51
66
8.88
38.03
1.3
1.8
13.51
75.20
e6/l
0.90
41
51
36
28
14.23
38.00
2.3
1.4
—
—
—
0
0
282
1546
5.35
37.80
7.7
6.6
0.50
0.52
e9/l
1.11
264
1380
282
1547
5.34
37.74
7.8
6.7
0.04
0.04
e9/l
0.17
264
1379
86
196
5.50
37.26
2.3
1.8
1.23
1.38
g/l
0.38
79
187
196
836
4.08
37.25
2.3
2.8
2.33
2.35
mmol/l
1.46
184
786
50
65
8.82
37.12
1.2
1.8
1.03
16.52
e6/l
0.79
38
48
35
27
14.30
37.10
1.2
1.2
23.70
29.60
mg/l
0.59
30
21
113
331
4.57
36.04
1.7
1.3
82.72
149.11
u/ml
1.68
45
144
284
1596
5.24
36.02
7.8
6.7
1.96
1.97
e9/l
0.08
268
1459
286
1616
5.32
36.01
7.8
7.1
0.16
0.18
e9/l
1.77
273
1457
169
665
4.00
35.80
3.2
3.6
7.39
7.40
ph
1.38
132
459
302
1785
6.23
35.78
6.0
3.3
82.79
69.02
ug/l
1.19
296
1719
291
1712
5.27
33.52
8.8
9.6
3.84
3.92
e9/l
0.29
269
1511
33
28
12.92
32.99
2.0
1.4
3.12
3.06
g/l
0.04
26
20
33
28
12.92
32.99
2.0
1.4
0.33
0.39
g/l
0.41
26
21
33
28
12.92
32.99
2.0
1.4
5.97
6.28
g/l
0.23
26
21
56
96
6.76
32.45
1.2
1.3
—
—
—
0
0
129
451
3.96
31.83
2.6
2.3
525.63
548.99
mosm/kgh2o
0.52
119
397
179
789
3.61
30.93
3.2
2.7
18.53
65.30
e6/l
1.43
147
588
35
36
10.70
30.83
1.5
2.0
1.35
3.06
mmol/l
2.52
20
28
35
36
10.70
30.83
1.5
2.0
5.07
5.12
kpa
0.12
35
36
34
36
10.36
29.31
1.5
2.0
9.85
9.92
kpa
0.06
34
36
94
277
4.28
29.18
1.6
1.3
131.21
174.28
u/ml
0.28
88
252
251
1431
3.71
27.68
4.5
4.9
5.75
6.26
mmol/l
6.75
235
1290
157
676
3.41
27.45
3.1
2.5
0.09
0.28
e6/l
3.13
121
485
182
858
3.35
27.37
2.2
1.4
1.87
2.10
g/l
2.04
136
575
39
54
8.01
27.28
1.6
2.5
7.41
7.42
ph
0.25
39
54
38
52
8.08
26.84
2.1
1.5
0.52
0.47
g/l
0.17
31
42
198
993
3.31
26.63
4.2
3.3
20.86
40.45
e6/l
0.81
152
648
134
540
3.41
25.81
2.2
2.9
40.58
85.80
ug/g
6.26
101
429
241
1390
3.39
25.00
12.0
9.2
0.00
0.00
e9/l
0.95
204
1157
32
39
8.93
24.77
1.6
1.3
0.15
0.15
nmol/l
0.01
26
28
63
155
4.74
24.40
1.9
2.2
2.36
5.29
iu/ml
1.46
18
28
91
295
3.82
24.36
1.8
1.5
1163.51
1089.24
nmol/l
0.31
73
237
125
509
3.27
23.31
2.6
2.3
4.29
9.59
e6/l
2.43
114
461
109
409
3.42
23.23
2.1
2.1
2.39
2.41
mmol/l
0.59
93
363
162
783
3.00
22.19
3.6
2.7
25.63
20.30
ng/l
0.16
59
327
29
36
8.70
22.08
1.6
1.3
—
—
nmol/l
—
0
0
40
72
6.15
21.87
1.4
1.2
—
—
—
0
0
151
713
2.97
21.42
3.2
2.3
2.14
2.59
mg/l
3.69
135
631
101
382
3.32
21.02
2.6
2.4
3.10
3.74
e6/l
0.26
56
178
225
1332
2.95
20.65
5.2
5.7
9.40
10.18
umol/l
1.08
215
1278
183
972
2.86
20.65
1.7
1.4
2.08
1.90
u/ml
0.04
63
279
247
1547
3.06
20.25
4.4
3.1
0.07
4.67
estimate
0.49
71
323
248
1559
3.06
20.15
4.4
3.2
0.00
0.00
estimate
-0.00
73
311
245
1539
3.00
19.76
4.3
3.1
0.00
0.00
estimate
0.50
72
319
52
131
4.49
19.39
2.0
9.9
25.20
25.04
mmol/l
0.14
52
131
31
21
16.08
19.32
1.3
1.1
0.48
0.56
ratio
1.64
21
11
40
83
5.32
18.76
1.6
1.1
7.58
16.38
au/ml
1.02
13
33
45
105
4.77
18.42
1.1
1.8
—
10.23
—
0
6
328
2508
6.36
18.41
7.8
4.5
14.49
14.26
pmol/l
1.17
323
2378
26
36
7.72
18.05
1.6
2.5
—
—
—
0
0
190
1081
2.67
17.98
3.5
3.2
23.86
27.66
u/l
2.10
185
1042
161
854
2.65
17.44
6.0
5.9
—
—
—
0
0
339
2852
8.29
17.23
9.5
5.3
1.61
1.71
mu/l
1.30
334
2748
32
59
5.87
16.99
1.2
1.9
—
—
—
0
0
27
18
16.15
16.96
1.8
3.3
356.59
429.00
u/ml
0.56
27
18
24
12
21.37
16.66
1.5
1.1
119.25
185.17
mmol/24h
1.91
24
12
155
825
2.58
16.45
3.9
4.5
—
—
—
0
0
137
691
2.62
16.21
2.3
2.0
0.36
0.78
mg/l
3.98
92
515
137
699
2.58
15.74
1.5
1.3
363.17
22.64
iu/ml
0.49
29
201
89
367
2.91
15.49
1.4
1.2
—
—
—
0
0
37
86
4.70
15.16
1.4
2.6
—
—
—
0
0
191
1163
2.42
14.65
2.0
2.2
—
—
—
0
0
32
68
5.08
14.55
1.3
1.4
—
—
—
0
0
165
944
2.42
14.53
3.5
2.5
0.78
0.03
estimate
0.47
64
267
146
795
2.44
14.31
4.3
3.2
0.00
0.01
estimate
1.08
73
318
61
211
3.29
14.31
2.4
2.9
0.25
0.23
g/l
1.47
56
204
194
1199
2.40
14.25
4.0
2.9
0.00
0.03
estimate
0.96
63
276
133
699
2.46
14.04
3.5
2.9
1.02
1.02
kg/l
2.14
98
452
322
2571
4.38
13.71
5.4
4.3
35.57
36.99
mmol/mol
3.22
317
2483
124
644
2.44
13.32
1.5
1.3
1.31
9.41
u/ml
2.22
48
271
198
1265
2.31
13.07
3.1
2.8
6.06
6.17
ph
0.70
111
747
148
838
2.33
12.99
5.1
6.1
1.02
1.06
inr
1.86
130
697
88
393
2.66
12.95
1.7
1.4
22.02
21.77
iu/l
0.03
77
342
86
380
2.68
12.92
3.3
2.8
106.72
249.86
ng/l
0.83
29
193
30
69
4.66
12.42
1.4
1.4
341.50
354.22
ug/g
0.08
14
38
69
292
2.70
11.18
1.3
1.4
—
—
—
0
0
68
286
2.71
11.14
2.2
2.9
29.57
29.92
s
0.26
68
281
117
635
2.27
11.02
3.6
2.4
—
—
—
0
0
56
217
2.88
10.69
1.1
1.1
—
—
—
0
0
10
0
+∞
10.47
1.3
0.0
870.70
—
nmol/l
—
10
0
38
120
3.43
10.21
1.1
1.1
2.40
6.77
u/ml
1.50
23
69
339
3048
5.34
9.48
20.9
10.8
15.29
19.25
mg/l
1.82
287
2399
22
32
7.26
9.48
1.1
2.3
—
—
—
0
0
17
16
11.10
9.39
1.8
2.4
2.28
1.91
nmol/l
0.21
17
16
72
337
2.43
9.38
1.4
1.2
—
—
—
0
0
46
172
2.93
9.33
1.4
1.4
11.75
10.32
u/l
0.20
35
139
48
185
2.85
9.22
4.1
5.8
7.36
7.38
ph
1.44
36
102
48
185
2.85
9.22
3.2
2.1
13.58
12.74
nmol/l
0.26
43
177
49
191
2.82
9.22
1.3
1.2
—
—
—
0
0
97
525
2.18
8.95
3.6
3.6
—
—
—
0
0
21
32
6.91
8.80
1.1
1.2
—
—
—
0
0
46
179
2.81
8.67
4.2
5.8
2.15
1.60
mmol/l
0.62
40
153
75
371
2.30
8.57
1.3
1.4
—
—
—
0
0
57
249
2.54
8.56
4.1
3.0
—
—
—
0
0
52
219
2.62
8.41
1.2
1.1
—
144.00
—
0
5
20
32
6.56
8.14
2.4
5.5
151.06
48.27
u/ml
—
5
11
20
32
6.56
8.14
1.2
1.2
—
—
—
0
0
20
47
4.45
8.05
1.2
1.1
8.54
12.12
u/ml
—
9
26
52
224
2.55
8.02
6.0
5.0
0.00
0.16
%
—
7
49
19
29
6.86
8.00
1.3
2.1
18.81
17.42
%
1.39
19
29
37
134
2.97
7.93
1.5
1.5
0.26
0.36
nmol/l
1.47
31
113
317
2713
2.89
7.87
4.8
3.5
5.50
5.60
mmol/l
0.90
307
2585
34
118
3.09
7.84
3.6
6.9
23.50
24.09
mmol/l
0.47
34
118
52
227
2.52
7.80
6.1
5.2
0.00
0.39
%
—
7
44
22
58
3.98
7.65
2.0
4.5
9.50
8.77
kpa
1.21
22
58
52
233
2.45
7.37
6.0
4.8
1.00
1.01
%
—
7
60
43
179
2.60
7.10
1.4
1.7
0.15
0.27
mg/l
—
6
79
32
114
2.99
7.06
1.2
1.1
0.77
0.62
u/ml
0.09
17
53
12
12
10.31
6.58
1.1
1.2
67.23
75.42
nmol/24h
0.17
12
12
17
30
5.90
6.54
1.5
1.3
—
—
—
0
0
50
233
2.34
6.49
1.7
1.8
0.00
0.05
estimate
0.49
18
62
10
7
14.66
6.43
1.1
1.0
—
—
titre
—
0
0
48
223
2.34
6.27
1.2
1.1
—
—
—
0
0
278
2320
1.99
6.18
4.0
3.2
29.12
33.36
u/l
1.22
273
2251
31
118
2.79
6.08
1.2
1.1
0.80
1.50
u/ml
0.48
15
57
116
751
1.82
6.08
3.7
2.1
—
—
—
0
0
11
11
10.28
6.07
1.5
2.7
2062.27
2117.73
ml
0.06
11
11
166
1194
1.75
6.06
2.2
1.9
—
—
—
0
0
54
270
2.18
5.92
3.5
2.4
29.96
31.96
u/l
0.21
49
226
17
36
4.91
5.69
1.1
2.1
1432.36
1437.69
e6/l
0.01
11
29
9
7
13.15
5.61
1.0
1.0
4.45
5.43
mg/g
—
9
7
46
221
2.25
5.55
4.8
4.6
0.83
0.79
%
—
6
52
41
189
2.33
5.45
2.1
3.6
1.28
1.83
%
5.61
32
173
37
165
2.39
5.29
3.5
10.0
—
—
—
0
0
60
326
2.02
5.29
1.8
1.5
—
—
—
0
0
18
54
3.46
5.24
2.7
2.2
0.29
1.97
index
—
7
26
94
595
1.79
5.20
2.0
2.3
292.25
305.03
umol/l
0.77
85
561
12
19
6.50
5.12
1.1
1.6
0.22
0.30
e9/l
—
6
10
61
338
1.98
5.08
2.0
2.8
4.30
5.86
umol/l
0.97
50
292
48
244
2.12
5.04
6.5
7.6
104.02
104.75
mmol/l
0.63
48
244
65
373
1.91
4.88
2.0
3.0
3.84
4.97
e9/l
0.73
60
342
32
139
2.43
4.85
1.2
1.1
0.16
3.13
u/ml
2.89
16
77
32
140
2.42
4.78
1.2
2.1
—
—
—
0
0
23
87
2.76
4.59
1.2
1.1
0.01
0.32
u/ml
—
5
25
26
105
2.60
4.58
1.2
1.0
0.55
3.58
u/ml
1.83
11
46
15
44
3.52
4.52
1.3
2.4
4.82
6.77
pmol/l
1.02
15
44
12
23
5.36
4.49
1.1
1.0
135.42
120.09
pmol/l
0.44
12
23
14
32
4.51
4.49
1.1
2.0
518.00
549.37
e6/l
—
8
24
29
125
2.44
4.48
2.4
3.3
59.00
77.87
e9/l
3.16
21
88
14
33
4.38
4.37
1.1
1.8
269.25
230.19
e6/l
—
8
26
21
78
2.80
4.33
1.0
1.1
3.01
2.18
eliau/ml
—
7
40
17
56
3.14
4.30
1.1
1.2
—
—
—
0
0
44
233
2.02
4.15
1.2
1.2
—
—
—
0
0
23
93
2.58
4.05
1.3
1.1
2.78
5.99
u/ml
—
8
34
14
36
4.01
4.04
1.6
1.2
—
—
—
0
0
55
319
1.86
3.98
1.7
2.1
—
—
—
0
0
12
27
4.56
3.97
1.2
1.1
—
—
—
0
0
14
43
3.35
3.95
1.3
1.1
—
—
—
0
0
22
89
2.57
3.88
1.7
2.4
205.63
93.42
ng/l
0.34
16
78
14
38
3.79
3.84
1.4
1.9
45.17
42.74
%
0.32
14
38
9
15
6.13
3.84
1.0
1.7
132.89
172.80
nmol/l
—
9
15
57
339
1.81
3.81
1.5
1.4
—
—
—
0
0
7
8
8.90
3.79
1.7
2.6
1.34
1.50
ug/l
—
7
8
23
97
2.47
3.73
1.2
1.3
—
—
—
0
0
40
215
1.97
3.63
2.3
1.9
6.23
6.22
ph
0.03
32
125
21
86
2.53
3.62
11.0
9.7
—
—
—
0
0
27
125
2.26
3.58
1.6
2.4
2.41
4.69
iu/l
—
9
56
11
26
4.33
3.53
1.2
1.1
161.23
172.42
iu/ml
0.07
11
26
34
174
2.06
3.53
7.7
11.6
7.42
7.42
ph
0.29
20
107
15
52
2.97
3.51
1.7
2.3
142.47
133.95
g/l
1.40
15
42
10
24
4.26
3.22
1.3
1.8
1.84
1.65
mmol/l
—
10
24
8
15
5.43
3.21
1.0
1.1
—
—
—
0
0
54
337
1.71
3.07
2.3
2.1
1301.38
5856.72
u/l
1.86
18
142
9
21
4.37
3.01
1.6
2.0
—
—
—
0
0
27
137
2.05
2.89
2.0
1.8
16.51
6.39
u/ml
—
8
39
337
3201
2.67
2.80
16.4
9.5
—
—
—
0
0
82
582
1.53
2.77
1.4
1.6
—
—
—
0
0
16
66
2.49
2.75
1.3
1.3
4.55
3.80
u/ml
0.13
11
30
11
34
3.31
2.75
1.6
3.3
16.61
16.48
mu/l
0.01
11
34
15
60
2.57
2.74
1.5
4.5
4.06
4.04
e9/l
0.02
15
60
20
92
2.25
2.73
2.3
2.0
—
—
—
0
0
31
171
1.89
2.64
8.4
11.7
1.47
0.88
mmol/l
0.36
23
144
17
74
2.36
2.62
1.6
4.2
59.35
57.74
%
0.20
17
74
10
30
3.40
2.62
1.3
1.2
—
—
—
0
0
7
15
4.74
2.61
1.3
1.0
—
—
—
0
0
9
25
3.67
2.59
1.0
1.1
2745.22
1521.24
miu/ml
—
9
25
5
7
7.23
2.55
1.0
1.0
—
—
—
0
0
5
7
7.23
2.55
1.0
1.0
—
—
—
0
0
21
102
2.13
2.53
1.4
1.3
—
—
—
0
0
7
16
4.44
2.48
1.0
1.2
—
—
—
0
0
311
2892
1.71
2.48
4.4
3.8
1.46
1.48
mmol/l
0.46
300
2788
144
1166
1.40
2.42
1.9
1.8
1.38
1.39
mmol/l
0.01
127
1062
8
22
3.70
2.38
1.3
1.6
5.02
5.43
mmol/l
—
8
22
311
2899
1.68
2.37
4.6
3.9
4.79
4.79
mmol/l
0.02
301
2804
312
2913
1.69
2.33
4.9
4.1
2.93
2.88
mmol/l
0.54
302
2815
20
99
2.08
2.31
5.1
5.5
0.52
0.60
%
0.62
20
99
45
293
1.62
2.20
1.2
1.7
—
—
—
0
0
24
130
1.91
2.18
1.3
1.8
0.00
0.02
estimate
0.49
15
53
21
109
1.99
2.15
1.4
1.4
—
—
—
0
0
30
177
1.76
2.10
1.2
1.2
—
—
—
0
0
6
15
4.05
2.04
1.7
1.3
0.00
0.00
estimate
—
6
15
40
258
1.62
2.04
2.7
1.7
—
—
—
0
0
10
38
2.68
2.02
1.0
1.1
0.09
0.15
u/ml
—
5
16
5
11
4.59
1.95
1.4
1.5
35.40
32.27
mmol/l
—
5
11
5
11
4.59
1.95
1.6
1.1
—
—
—
0
0
5
11
4.59
1.95
1.2
1.1
0.04
1.64
u/ml
—
5
11
99
777
1.38
1.94
2.4
3.0
9.33
8.66
mmol/l
0.44
94
695
29
176
1.71
1.86
1.6
1.4
—
—
—
0
0
111
896
1.35
1.81
2.0
2.1
—
—
—
0
0
46
316
1.53
1.81
1.2
1.6
—
—
—
0
0
46
319
1.51
1.74
1.2
1.6
—
—
—
0
0
11
225
0.47
1.70
1.3
1.6
—
—
—
0
0
10
209
0.46
1.64
1.1
1.1
—
0.54
—
0
17
14
70
2.04
1.61
1.1
1.1
—
—
—
0
0
45
316
1.49
1.61
1.2
1.7
—
—
—
0
0
11
220
0.48
1.60
1.3
1.5
—
—
—
0
0
45
317
1.48
1.59
1.2
1.6
—
—
—
0
0
51
375
1.42
1.45
1.5
1.5
—
—
—
0
0
5
16
3.15
1.44
1.4
1.1
98.18
186.62
pmol/l
—
5
16
9
39
2.34
1.44
1.2
2.4
—
—
—
0
0
18
103
1.79
1.43
1.2
1.1
—
—
—
0
0
6
23
2.64
1.37
2.0
1.2
34.50
33.39
pg
—
6
23
96
791
1.30
1.32
1.6
1.9
—
—
—
0
0
6
25
2.42
1.25
1.0
1.3
—
—
—
0
0
6
25
2.42
1.25
1.0
1.3
—
—
—
0
0
6
25
2.42
1.25
2.0
1.5
54.00
70.36
umol/l
—
6
25
6
25
2.42
1.25
5.5
13.0
10.20
10.41
%
—
6
25
6
25
2.42
1.25
1.0
1.3
—
—
—
0
0
6
25
2.42
1.25
1.0
1.3
—
—
—
0
0
288
2724
1.33
1.22
3.9
3.3
1.23
1.21
mmol/l
0.17
276
2610
8
37
2.19
1.22
1.4
1.1
26.91
34.12
nmol/l
—
8
27
5
19
2.65
1.22
1.0
1.2
550.80
463.58
nmol/l
—
5
19
22
142
1.59
1.17
3.9
4.5
2.13
8.83
ug/l
2.09
17
108
20
127
1.61
1.14
1.4
1.1
—
—
—
0
0
10
51
1.99
1.12
2.4
2.3
—
—
—
0
0
11
59
1.89
1.08
1.0
1.1
—
—
—
0
0
13
213
0.60
1.03
1.1
1.1
1.65
1.56
g/l
0.54
13
213
17
107
1.62
1.01
2.1
1.7
—
—
—
0
0
15
92
1.66
0.98
2.4
3.5
—
—
—
0
0
5
23
2.19
0.98
2.0
1.6
—
—
—
0
0
28
200
1.44
0.97
2.1
1.9
22.65
35.84
u/ml
0.69
28
192
48
377
1.32
0.95
1.2
1.2
—
—
—
0
0
14
216
0.63
0.89
1.1
1.1
0.91
0.89
g/l
0.16
14
216
6
31
1.95
0.85
1.2
2.1
0.94
0.79
e9/l
—
6
31
83
709
1.22
0.84
1.9
1.6
—
—
—
0
0
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
6
34
1.78
0.76
1.0
1.0
—
—
—
0
0
5
26
1.94
0.71
1.4
1.2
—
—
—
0
0
9
59
1.54
0.69
5.6
3.0
8.00
528.54
u/ml
—
9
52
37
296
1.28
0.67
2.2
1.7
—
—
—
0
0
108
966
1.17
0.66
1.6
1.8
—
—
—
0
0
11
70
1.59
0.66
1.0
1.1
—
—
—
0
0
16
112
1.45
0.64
1.2
1.1
—
—
—
0
0
16
112
1.45
0.64
1.2
1.1
—
—
—
0
0
156
1445
1.14
0.59
2.5
2.4
—
—
—
0
0
12
81
1.50
0.57
1.3
3.9
207.20
397.61
mg/l
—
5
46
66
581
1.17
0.50
3.2
3.9
22.55
10.52
mg/mmol
0.32
41
379
5
32
1.57
0.42
2.4
2.0
5.62
6.64
mmol/l
—
5
32
18
141
1.29
0.41
2.6
2.0
0.57
0.65
ug/l
—
10
51
9
70
1.29
0.37
1.2
1.1
—
—
—
0
0
6
41
1.47
0.36
2.2
1.3
—
—
—
0
0
12
91
1.33
0.34
1.3
1.3
—
—
—
0
0
6
45
1.34
0.34
2.0
1.6
6.30
7.59
mmol/l
—
6
45
5
39
1.29
0.23
2.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
3034.60
—
0
5
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
39.2
—
6.74
—
0
13
62
579
1.09
0.20
2.7
3.3
87.10
60.51
mg/l
0.17
35
384
142
1377
1.05
0.16
2.5
2.7
—
—
estimate
—
0
0
44
421
1.05
0.08
2.0
1.6
3.16
3.42
mmol/l
0.77
30
295
108
1104
0.97
0.08
1.6
1.7
—
—
—
0
0
8
78
1.03
0.07
19.5
6.3
—
—
—
0
0
11
119
0.92
0.04
2.5
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
78.88
—
0
8
0
9
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
23
230
1.00
-0.00
1.3
1.3
247.00
258.82
miu/ml
—
9
115
0
6
0.00
-0.00
0.0
1.7
—
12.43
—
0
6
0
5
0.00
-0.00
0.0
1.8
—
364.80
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint G6_POSTVIRFAT and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have G6_POSTVIRFAT.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: G6_POSTVIRFAT – Postviral fatigue syndrome

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data